|
Synonyms: IPH-4102 | IPH4102
Compound class:
Antibody
Comment: Lacutamab (IPH4102) is a humanized anti-KIR3DL2, cytotoxicity-inducing, monoclonal antibody [3-4,6].
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
| References |
|
1. Bagot M, Porcu P, Marie-Cardine A, Battistella M, William BM, Vermeer M, Whittaker S, Rotolo F, Ram-Wolff C, Khodadoust MS et al.. (2019)
IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphoma: an international, first-in-human, open-label, phase 1 trial. Lancet Oncol, 20 (8): 1160-1170. [PMID:31253572] |
|
2. Bonnafous C, Sicard H, Buffet R. (2014)
A compound that specifically binds to kir3dl2 for use in the treatment of peripheral t cell lymphoma. Patent number: WO2014128221A1. Assignee: Innate Pharma. Priority date: 20/02/2013. Publication date: 28/08/2014. |
|
3. Gauthier L, Schneider N. (2019)
Humanized antibodies with increased stability. Patent number: US10280222B2. Assignee: Innate Pharma SA. Priority date: 12/03/2015. Publication date: 07/05/2019. |
|
4. Marie-Cardine A, Viaud N, Thonnart N, Joly R, Chanteux S, Gauthier L, Bonnafous C, Rossi B, Bléry M, Paturel C et al.. (2014)
IPH4102, a humanized KIR3DL2 antibody with potent activity against cutaneous T-cell lymphoma. Cancer Res, 74 (21): 6060-70. [PMID:25361998] |
|
5. Sicard H, Bonnafous C, Morel A, Bagot M, Bensussan A, Marie-Cardine A. (2015)
A novel targeted immunotherapy for CTCL is on its way: Anti-KIR3DL2 mAb IPH4102 is potent and safe in non-clinical studies. Oncoimmunology, 4 (9): e1022306. [PMID:26405593] |
|
6. Van Der Weyden C, Bagot M, Neeson P, Darcy PK, Prince HM. (2018)
IPH4102, a monoclonal antibody directed against the immune receptor molecule KIR3DL2, for the treatment of cutaneous T-cell lymphoma. Expert Opin Investig Drugs, 27 (8): 691-697. [PMID:30001170] |